UCB SA - UCBJY STOCK NEWS

Welcome to our dedicated news page for UCB SA (Ticker: UCBJY), a resource for investors and traders seeking the latest updates and insights on UCB SA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect UCB SA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of UCB SA's position in the market.

04/12/2024 07:00 AM

News

UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting

Rhea-AI Summary

UCB presents new data analyses for gMG treatments and epilepsy syndromes at AAN 2024, showcasing commitment to patients and innovative solutions.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.29%

Tags

04/10/2024 08:00 AM

News

UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

Rhea-AI Summary

UCBJY launches new campaign offering resources and information to investors

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.24%

Tags

04/04/2024 07:00 AM

News

FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Rhea-AI Summary

UCB's BIMZELX (bimekizumab-bkzx) shows positive results in Phase 3 studies for moderate-to-severe hidradenitis suppurativa treatment. FDA accepts sBLA for BIMZELX and 2mL device presentations, expanding treatment options for patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.15%

Tags

03/09/2024 12:00 PM

News

First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

Rhea-AI Summary

UCB presents positive four-year efficacy and safety data for BIMZELX at AAD 2024, showing high rates of clinical responses and tolerability in psoriasis patients. Over six out of ten patients achieved complete skin clearance at Year 4, with consistent safety profiles. The majority of patients maintained their responses to PASI90 and PASI100 through four years, indicating the potential of BIMZELX to transform the lives of patients with moderate-to-severe plaque psoriasis.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/08/2024 12:00 PM

News

BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

Rhea-AI Summary

UCB's BIMZELX Shows Positive Results in Hidradenitis Suppurativa Study at AAD 2024

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.08%

Tags

02/28/2024 07:03 AM

News

UCB on Growth Path for a Decade Plus

Rhea-AI Summary

UCB reports FY 2023 revenue of €5.25 billion, net sales of €4.87 billion, and strong performance by growth drivers. The company achieved a 7% increase in adjusted EBITDA, with financial guidance for 2024 projecting revenue growth to €5.5-5.7 billion. UCB's CEO highlights the company's commitment to patient access and sustainability efforts.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.82%

Tags

01/03/2024 07:00 AM

News

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

Rhea-AI Summary

UCB Announces Commercial Availability of ZILBRYSQ (zilucoplan) in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-AChR Antibody Positive

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.76%

Tags

12/02/2023 07:00 AM

News

UCB presents new data about the real-world experience of FINTEPLA® (fenfluramine) and rare epilepsy syndromes at 2023 American Epilepsy Society (AES) Annual Meeting

Rhea-AI Summary

Study on Zogenix Inc. (ZGNX) FINTEPLA Shows Positive Efficacy and Tolerability Over 12 Months

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

12/01/2023 07:00 AM

News

UCB presents new data advancing patient-focused scientific leadership at American Epilepsy Society Annual Meeting

Rhea-AI Summary

UCB, a global biopharmaceutical company, will present 29 abstracts, including 4 late breakers, at the American Epilepsy Society Annual Meeting 2023. The presentations will highlight clinical, health economic, and demographic studies in epilepsy, demonstrating the diversity, potential, and momentum of UCB's epilepsy and rare syndromes portfolio, including important fenfluramine and brivaracetam data.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.63%

Tags

11/14/2023 07:00 AM

News

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Rhea-AI Summary

UCB - BIMZELX® (bimekizumab-bkzx) is now commercially available by prescription in the United States. It is the first and only IL-17A and IL-17F inhibitor approved for treating adults with moderate-to-severe plaque psoriasis. BIMZELX Navigate™, a personalized patient support system, is also available to eligible patients to provide support during treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.12%

Tags